[P02BB01, trichlorfon, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Oxybutynin.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Oxybutynin.]
[N05AL01, sulpiride, Oxybutynin may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06DA01, tacrine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Oxybutynin.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Oxybutynin.]
[R03CC03, terbutaline, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Terbutaline.]
[G03BA03, testosterone, The metabolism of Oxybutynin can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Oxybutynin.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Oxybutynin.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AX02, thalidomide, Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Oxybutynin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Oxybutynin.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Oxybutynin.]
[B02AB01, aprotinin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Oxybutynin.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Oxybutynin.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Oxybutynin.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Oxybutynin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Oxybutynin.]
[S01BA05, triamcinolone, The metabolism of Oxybutynin can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxybutynin.]
[R03BA07, mometasone, The metabolism of Oxybutynin can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Trimethaphan.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Oxybutynin.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Oxybutynin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Tropicamide is combined with Oxybutynin.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Oxybutynin.]
[S01AA05, tyrothricin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Oxybutynin.]
[A10BH05, linagliptin, The metabolism of Oxybutynin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Oxybutynin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Oxybutynin can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Oxybutynin.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Oxybutynin.]
[C08DA01, verapamil, The metabolism of Oxybutynin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Oxybutynin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Oxybutynin.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Oxybutynin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Oxybutynin.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Oxybutynin.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Oxybutynin.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AE02, indinavir, The metabolism of Oxybutynin can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Oxybutynin.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Oxybutynin.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Oxybutynin.]
[N05AE04, ziprasidone, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Oxybutynin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Oxybutynin.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Oxybutynin.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Oxybutynin.]
[J02AC03, voriconazole, The metabolism of Oxybutynin can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Oxybutynin.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Oxybutynin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Oxybutynin.]
[H02AB11, prednylidene, The metabolism of Oxybutynin can be increased when combined with Prednylidene.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Oxybutynin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Oxybutynin is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Oxybutynin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Oxybutynin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Oxybutynin.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Oxybutynin.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Octopamine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Oxybutynin.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AE04, nelfinavir, The metabolism of Oxybutynin can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08CA13, lercanidipine, The metabolism of Oxybutynin can be decreased when combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06DA02, donepezil, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Oxybutynin.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Oxybutynin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Oxybutynin.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Oxybutynin.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Oxybutynin.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Oxybutynin.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Oxybutynin.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Oxybutynin.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Oxybutynin.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Oxybutynin.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Oxybutynin.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Oxybutynin.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Oxybutynin.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Oxybutynin.]
[L01EC02, dabrafenib, The serum concentration of Oxybutynin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Oxybutynin.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Oxybutynin.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Oxybutynin.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AP05, simeprevir, The metabolism of Oxybutynin can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Oxybutynin.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Droxidopa.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Oxybutynin.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A16AA07, metreleptin, The metabolism of Oxybutynin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Oxybutynin can be increased when combined with Apremilast.]
[A16AA06, betaine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The metabolism of Oxybutynin can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Oxybutynin.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Oxybutynin.]
[L04AC11, siltuximab, The metabolism of Oxybutynin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Oxybutynin.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Oxybutynin.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxybutynin.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Oxybutynin.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Oxybutynin.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Oxybutynin.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Glycopyrronium.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Oxybutynin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[V04CX03, methacholine, Oxybutynin may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Oxybutynin.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Oxybutynin.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Oxybutynin.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Oxybutynin.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Oxybutynin.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Oxybutynin.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Oxybutynin.]
[N06AX11, mirtazapine, Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AC10, secukinumab, The metabolism of Oxybutynin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Oxybutynin.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Oxybutynin.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Oxybutynin.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Oxybutynin.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Difemerine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Oxybutynin.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Oxybutynin is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Oxybutynin.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Oxybutynin.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Oxybutynin.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Oxybutynin.]
[J02AC05, isavuconazole, The metabolism of Oxybutynin can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Oxybutynin.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Oxybutynin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Oxybutynin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Oxybutynin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Oxybutynin.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Oxybutynin.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Oxybutynin.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Oxybutynin.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Oxybutynin.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Oxybutynin.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Oxybutynin.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Oxybutynin.]
[N06DA03, rivastigmine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Oxybutynin.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.]
[S01GX07, azelastine, Azelastine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XK03, rucaparib, The metabolism of Oxybutynin can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Oxybutynin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Oxybutynin.]
[L01EF02, ribociclib, The metabolism of Oxybutynin can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Bambuterol.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Oxybutynin.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AE09, tipranavir, The metabolism of Oxybutynin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Oxybutynin.]
[L04AB02, infliximab, The metabolism of Oxybutynin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Oxybutynin can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Oxybutynin.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Oxybutynin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Oxybutynin.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Oxybutynin.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Oxybutynin.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Bitolterol is combined with Oxybutynin.]
[J05AG03, efavirenz, The metabolism of Oxybutynin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Oxybutynin.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03BA02, budesonide, The metabolism of Oxybutynin can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Oxybutynin.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AX18, letermovir, The metabolism of Oxybutynin can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01BX04, capsaicin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Oxybutynin.]
[L02BB05, apalutamide, The metabolism of Oxybutynin can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Oxybutynin.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Oxybutynin.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Oxybutynin.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia and drowsiness can be increased when Oxybutynin is combined with Cannabidiol.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Oxybutynin.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Oxybutynin.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Oxybutynin.]
[L01XX62, ivosidenib, The metabolism of Oxybutynin can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Oxybutynin.]
[N03AX17, stiripentol, The metabolism of Oxybutynin can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Oxybutynin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Oxybutynin.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Oxybutynin.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Chlorphenoxamine.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Oxybutynin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Oxybutynin.]
[L04AA39, emapalumab, The metabolism of Oxybutynin can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Oxybutynin.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Oxybutynin.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Oxybutynin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Oxybutynin.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Oxybutynin.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Oxybutynin.]
[J01FA09, clarithromycin, The metabolism of Oxybutynin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Oxybutynin.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Oxybutynin.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H02AB14, cloprednol, The metabolism of Oxybutynin can be increased when combined with Cloprednol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Oxybutynin.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AB01, etanercept, The metabolism of Oxybutynin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Oxybutynin can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Oxybutynin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Oxybutynin.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Oxybutynin.]
[N07XX11, pitolisant, The serum concentration of Oxybutynin can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Oxybutynin.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Oxybutynin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Oxybutynin.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Oxybutynin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Oxybutynin.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Oxybutynin.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Oxybutynin.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Oxybutynin.]
[N03AX25, cenobamate, The serum concentration of Oxybutynin can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Oxybutynin.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Oxybutynin.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H02CA02, osilodrostat, The metabolism of Oxybutynin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Oxybutynin can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Oxybutynin.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Oxybutynin.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Oxybutynin.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Oxybutynin.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Oxybutynin.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S03AA08, chloramphenicol, The metabolism of Oxybutynin can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Oxybutynin.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Dopexamine.]
[D07XB03, fluprednidene, The metabolism of Oxybutynin can be increased when combined with Fluprednidene.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Oxybutynin.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Oxybutynin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Oxybutynin.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AC19, satralizumab, The serum concentration of Oxybutynin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of urinary retention, reduced gastrointestinal motility, and constipation can be increased when Oxybutynin is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Oxybutynin.]
[L01EX23, pralsetinib, The metabolism of Oxybutynin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[B06AC06, berotralstat, The metabolism of Oxybutynin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Oxybutynin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Oxybutynin.]
[P03AX07, abametapir, The serum concentration of Oxybutynin can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Fenozolone.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Oxybutynin.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Oxybutynin.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Oxybutynin.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A02BA01, cimetidine, The metabolism of Oxybutynin can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Oxybutynin.]
[L01XX73, sotorasib, The serum concentration of Oxybutynin can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Oxybutynin.]
[S03AA07, ciprofloxacin, The metabolism of Oxybutynin can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Oxybutynin.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Oxybutynin.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Oxybutynin.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Oxybutynin.]
[N06AX25, St. John's wort extract, The metabolism of Oxybutynin can be increased when combined with St. John's Wort.]
[J04BA01, clofazimine, The metabolism of Oxybutynin can be decreased when combined with Clofazimine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Oxybutynin.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Oxybutynin.]
[C01EB24, mavacamten, The serum concentration of Oxybutynin can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Oxybutynin.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H01AC08, somatrogon, The metabolism of Oxybutynin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Oxybutynin.]
[L04AC21, bimekizumab, The metabolism of Oxybutynin can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Oxybutynin.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Oxybutynin.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Oxybutynin.]
[J01FA15, telithromycin, The metabolism of Oxybutynin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Oxybutynin.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H01AX01, pegvisomant, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J02AC02, itraconazole, The metabolism of Oxybutynin can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Oxybutynin.]
[J02AC04, posaconazole, The metabolism of Oxybutynin can be decreased when combined with Posaconazole.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Oxybutynin.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01BA03, cortisone, The metabolism of Oxybutynin can be increased when combined with Cortisone.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AX13, loratadine, Oxybutynin may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Oxybutynin.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Oxybutynin.]
[H02AB15, meprednisone, The metabolism of Oxybutynin can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Oxybutynin.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Oxybutynin.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Oxybutynin.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03DA04, eplerenone, The metabolism of Oxybutynin can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Oxybutynin.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Oxybutynin.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Oxybutynin.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BA07, modafinil, The metabolism of Oxybutynin can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Oxybutynin.]
[C03XA02, conivaptan, The metabolism of Oxybutynin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Oxybutynin.]
[G03XA01, danazol, The metabolism of Oxybutynin can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Oxybutynin.]
[L01DB02, daunorubicin, The metabolism of Oxybutynin can be increased when combined with Daunorubicin.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Oxybutynin.]
[A04AD11, nabilone, The risk or severity of Tachycardia and drowsiness can be increased when Oxybutynin is combined with Nabilone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Oxybutynin.]
[N06AX06, nefazodone, The metabolism of Oxybutynin can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Normethadone.]
[N06AB10, escitalopram, Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Oxybutynin.]
[N06AA01, desipramine, The metabolism of Desipramine can be decreased when combined with Oxybutynin.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S03BA01, dexamethasone, The metabolism of Oxybutynin can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dexetimide.]
[S01AA13, fusidic acid, The metabolism of Oxybutynin can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Oxybutynin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Oxybutynin.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Oxybutynin.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextromoramide.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[B01AC04, clopidogrel, The metabolism of Oxybutynin can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Oxybutynin.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Oxybutynin.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Oxybutynin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Oxybutynin.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be decreased when combined with Oxybutynin.]
[C08CA03, isradipine, The metabolism of Oxybutynin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Oxybutynin can be increased when combined with Difluocortolone.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Poldine.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Oxybutynin.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Oxybutynin.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Oxybutynin.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Oxybutynin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Oxybutynin.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08DB01, diltiazem, The metabolism of Oxybutynin can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Oxybutynin.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxybutynin.]
[N07AA03, distigmine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The metabolism of Oxybutynin can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Oxybutynin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Oxybutynin can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Oxybutynin.]
[A04AD12, aprepitant, The metabolism of Oxybutynin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Oxybutynin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Oxybutynin.]
[G04BE08, tadalafil, The metabolism of Oxybutynin can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Oxybutynin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Oxybutynin.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Oxybutynin.]
[R03AC12, salmeterol, The metabolism of Oxybutynin can be decreased when combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Dobutamine is combined with Oxybutynin.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Oxybutynin.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Oxybutynin.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Oxybutynin.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Oxybutynin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Oxybutynin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Oxybutynin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Oxybutynin.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Oxybutynin.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[V04CX07, edrophonium, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Oxybutynin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Oxybutynin.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Oxybutynin.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Oxybutynin.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Oxybutynin.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Oxybutynin is combined with Topiramate.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Oxybutynin.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Oxybutynin.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Oxybutynin.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Oxybutynin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Epinephrine is combined with Oxybutynin.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Oxybutynin.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02CA02, ergotamine, The metabolism of Oxybutynin can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Oxybutynin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Oxybutynin.]
[R03BA09, fluticasone furoate, The metabolism of Oxybutynin can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Oxybutynin can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Oxybutynin.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Oxybutynin.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Oxybutynin.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Oxybutynin.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Oxybutynin.]
[A02BA04, nizatidine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Nizatidine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Oxybutynin.]
[R06AX12, terfenadine, The metabolism of Oxybutynin can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Oxybutynin.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Oxybutynin.]
[C08CA02, felodipine, The metabolism of Oxybutynin can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Oxybutynin.]
[R03CC02, albuterol, The risk or severity of Tachycardia can be increased when Salbutamol is combined with Oxybutynin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Oxybutynin.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Oxybutynin.]
[J02AC01, fluconazole, The metabolism of Oxybutynin can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[D07AC08, fluocinonide, The metabolism of Oxybutynin can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H02AB03, fluocortolone, The metabolism of Oxybutynin can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Oxybutynin.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AF01, flupenthixol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L02BB01, flutamide, The metabolism of Oxybutynin can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Oxybutynin.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AE10, darunavir, The metabolism of Oxybutynin can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Oxybutynin.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Oxybutynin.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Oxybutynin.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Oxybutynin.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Oxybutynin.]
[A10BB01, glyburide, The metabolism of Oxybutynin can be decreased when combined with Glyburide.]
[H04AA01, glucagon, Oxybutynin may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Oxybutynin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Oxybutynin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Oxybutynin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Oxybutynin.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Oxybutynin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Oxybutynin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Oxybutynin.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Oxybutynin.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Oxybutynin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Oxybutynin.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Oxybutynin.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Oxybutynin.]
[C08CA10, nilvadipine, The metabolism of Oxybutynin can be decreased when combined with Nilvadipine.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Oxybutynin.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Oxybutynin can be decreased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Oxybutynin.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Oxybutynin.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Oxybutynin.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Oxybutynin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Oxybutynin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Oxybutynin.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Oxybutynin.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Oxybutynin.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Oxybutynin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Oxybutynin.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Oxybutynin.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Oxybutynin.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Oxybutynin.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Oxybutynin.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Oxybutynin.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Oxybutynin.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01EB07, isoflurophate, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J04AC01, isoniazid, The metabolism of Oxybutynin can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AC07, tocilizumab, The metabolism of Oxybutynin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J02AB02, ketoconazole, The metabolism of Oxybutynin can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AA24, abatacept, The metabolism of Oxybutynin can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Arbutamine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Oxybutynin.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Oxybutynin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Oxybutynin.]
[N07AA30, ambenonium, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxybutynin.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G03AD01, levonorgestrel, The metabolism of Oxybutynin can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Oxybutynin.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06BA13, armodafinil, The metabolism of Oxybutynin can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Oxybutynin.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Oxybutynin.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Oxybutynin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Oxybutynin.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxybutynin.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Oxybutynin.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01EA03, nilotinib, The metabolism of Oxybutynin can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Oxybutynin.]
[P01BC02, mefloquine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06DX01, memantine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Oxybutynin.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Oxybutynin.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H03BB02, methimazole, The metabolism of Oxybutynin can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Oxybutynin.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Methoxamine is combined with Oxybutynin.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Oxybutynin.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Oxybutynin.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Oxybutynin.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Oxybutynin.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Oxybutynin.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be decreased when combined with Oxybutynin.]
[P01AB01, metronidazole, The metabolism of Oxybutynin can be decreased when combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Oxybutynin.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Oxybutynin.]
[S02AA13, miconazole, The metabolism of Oxybutynin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Oxybutynin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Oxybutynin.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Oxybutynin.]
[G03XB01, mifepristone, The metabolism of Oxybutynin can be decreased when combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxybutynin.]
[L01XX23, mitotane, The metabolism of Oxybutynin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Oxybutynin.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01BD01, amiodarone, The metabolism of Oxybutynin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Oxybutynin.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AB05, certolizumab pegol, The metabolism of Oxybutynin can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Oxybutynin.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Oxybutynin.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Oxybutynin.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Oxybutynin.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Oxybutynin.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Oxybutynin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Oxybutynin can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Oxybutynin can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Naphazoline.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Oxybutynin.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Oxybutynin.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Oxybutynin.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Oxybutynin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Oxybutynin.]
[S01EB06, neostigmine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Oxybutynin.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08CA04, nicardipine, The metabolism of Oxybutynin can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Oxybutynin.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Oxybutynin.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Oxybutynin.]
[C08CA07, nisoldipine, The metabolism of Oxybutynin can be decreased when combined with Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08CA08, nitrendipine, The metabolism of Oxybutynin can be decreased when combined with Nitrendipine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Oxybutynin.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Oxybutynin.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Oxybutynin.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Oxybutynin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Oxybutynin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Oxybutynin.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Oxybutynin.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Oxymetazoline is combined with Oxybutynin.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxybutynin.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[H02AB05, paramethasone, The metabolism of Oxybutynin can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Oxybutynin.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Oxybutynin can be increased when combined with Pentobarbital.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Oxybutynin.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Oxybutynin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Oxybutynin.]
[N03AA02, phenobarbital, The metabolism of Oxybutynin can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Oxybutynin.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Oxybutynin.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Oxybutynin.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Oxybutynin.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Oxybutynin.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Oxybutynin.]
[L04AB06, golimumab, The metabolism of Oxybutynin can be increased when combined with Golimumab.]
[V03AB19, physostigmine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Oxybutynin.]
[C08CX01, mibefradil, The metabolism of Oxybutynin can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Oxybutynin.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Oxybutynin.]
[J05AE01, saquinavir, The metabolism of Oxybutynin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Oxybutynin.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Oxybutynin.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J05AG02, delavirdine, The metabolism of Oxybutynin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Oxybutynin.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Oxybutynin.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Oxybutynin.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Oxybutynin.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Oxybutynin.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L04AC08, canakinumab, The metabolism of Oxybutynin can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Oxybutynin.]
[J05AE03, ritonavir, The serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Oxybutynin.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Oxybutynin is combined with Potassium chloride.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Oxybutynin.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Oxybutynin.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P02BA01, praziquantel, The metabolism of Oxybutynin can be decreased when combined with Praziquantel.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P01BA03, primaquine, The metabolism of Oxybutynin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Oxybutynin can be increased when combined with Primidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Oxybutynin.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Oxybutynin.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Oxybutynin.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Oxybutynin.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Oxybutynin.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Oxybutynin.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Oxybutynin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Oxybutynin.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Oxybutynin.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Pseudoephedrine is combined with Oxybutynin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Oxybutynin.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Oxybutynin.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Oxybutynin.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[J04AB02, rifampin, The metabolism of Oxybutynin can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Oxybutynin is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Ritodrine is combined with Oxybutynin.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Oxybutynin.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Oxybutynin.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Oxybutynin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Oxybutynin.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Oxybutynin.]
[H02CA04, levoketoconazole, The metabolism of Oxybutynin can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Ipratropium.]
